CEL-SCI Corporation entered into a Placement Agency Agreement with ThinkEquity LLC on June 14, 2026, to sell 2,500,000 shares of common stock at $1.00 per share. The offering closed on June 16, 2026, generating $2,500,000 in gross proceeds. The company intends to use the net proceeds to fund Multikine development, general corporate purposes, and working capital. CEL-SCI Corporation is a biotechnology company focused on the development of therapeutic agents.